We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Genentech Breast Cancer Drug Denied Accelerated Approval
Genentech Breast Cancer Drug Denied Accelerated Approval
September 3, 2010
Genentech has been denied accelerated approval for its investigational breast cancer treatment trastuzumab-DM1 (T-DM1), a move likely to push the drug’s potential market entry back at least two years.